Antagonist fusion polypeptides
AssigneeKaida Biopharmaceuticals, Inc.
InventorsJohn Langenheim, Stephen Dunn
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antagonist fusion polypeptides (e.g., with extended half-life, improved antagonist activity) comprising (i) a serum albumin binding polypeptide; (ii) a polypeptide hormone analog capable of antagonizing its receptor activation; and (iii) a linker, as well as various related technologies including, methods of producing and using such fusion polypeptides.
Claims33
A fusion polypeptide comprising:
- (i) a serum albumin binding polypeptide;
- (ii) a polypeptide hormone analog capable of antagonizing its receptor activation;
- and
- (iii) a linker adjoining (i) and (ii),
- wherein (i) is N-terminal to the linker and (ii) is C-terminal to the linker.
(canceled)
(canceled)
(canceled)
(canceled)
-15. (canceled)
(canceled)
-23. (canceled)
-30. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of maintaining or improving functional activity of a polypeptide hormone analog in a fusion polypeptide, comprising N-terminally truncating the polypeptide hormone analog relative to the parental polypeptide hormone.
Dependencies are inferred from the claim text.